172@29@17@136!~!172@29@0@53!~!|news|business|markets|d-street-talk-podcast-i-was-not-expecting-this-a-traders-account-when-nifty-hit-lower-circuit-5033091.html?utm_source=MC_OpeninApp!~!news|moneycontrol|com!~!|controller|infinite_scroll_article.php!~!is_mobile=false
Moneycontrol
Subscribe to PRO at just Rs.33 per month. Use code SUPERPRO
Last Updated : Mar 14, 2020 01:59 PM IST | Source: Moneycontrol.com

D-Street Talk podcast | ‘I was not expecting this’: A traders account when Nifty hit lower circuit

In case any solution comes to fight the Coronavirus then it would act as the final bottom for the markets, suggest Chouhan. Technically, Nifty would remain in the range of 10200 and 9300 for the time being.

“I was not expecting this massive fall on Friday in the morning,” Shrikant Chouhan, SVP Technical Research, Kotak Securities told Moneycontrol in a special podcast ‘D-Street Talk’.

“On Thursday when SGX Nifty was down by more than 1000 points everyone was in fear, and to be honest prior to hitting a lower circuit, Nifty was trading well below all-important support levels, and that is why we are extremely cautious when Nifty hit a lower circuit,” explains Chouhan.

He further added that due to consistent watch on SGX and Dow Futures because we could see the real emotions from traders across the world which really helped. “If you remember when the market hit a lower circuit and there was 45-minute window, Dow futures and SGX turned green,” added Chouhan.

Close

This was an indication that the market could reverse the trend from here. It was clear that somebody has started covering their short positions in SGX which could well have a rub-off effect on Indian markets.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

From the day’s lowest levels we saw a rally of 1600 points on Nifty. We need to give time to our markets and world markets before deciding on a bottom for the market.

However, in case any solution comes to fight the Coronavirus then it would act as the final bottom for the markets, suggest Chouhan. Technically, Nifty would remain in the range of 10,200 and 9300 for the time being.

(Tune in to the podcast for more)

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
First Published on Mar 14, 2020 01:59 pm
Sections